Good News For Women With Newly-Diagnosed Ovarian Cancer — A Significant Increase in Survival Time With Promising New PARP Inhibitor Drugs

A specific PARP inhibitor called Zejula more than doubled the amount of time that many women with ovarian cancer lived without their cancer getting worse.

Published Sep 28, 2019

NOW
PLAYING
New Research Shows People With Cancer More Likely to Die of COVID-19 - Breaking Down the Data
NOW
PLAYING
You've Seen the Commercials Claiming Johnson & Johnson Baby Powder Causes Cancer - Is There Science to Back it Up?
NOW
PLAYING
Remembering Sen. Ted Kennedy, Who Loved Summer And The Sea - The Brain Cancer That Took His Life Now Has New Treatment Options
NOW
PLAYING
PARP Inhibitor Niraparib Now FDA Approved For Front-Line Ovarian Cancer Treatment
NOW
PLAYING
Rates of Advanced Prostate Cancer Have Gone Up Since Recommendations Started Advising Against PSA Test
NOW
PLAYING
Drive-Up Cancer Care? Exploring the Many Ways Care is Evolving Amid the COVID-19 Pandemic
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.